Based on the Insmed Inc stock forecast from 14 analysts, the average analyst target price for Insmed Inc is USD 75.91 over the next 12 months. Insmed Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Insmed Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Insmed Inc’s stock price was USD 70.60. Insmed Inc’s stock price has changed by -3.10% over the past week, -5.31% over the past month and +187.69% over the last year.
No recent analyst target price found for Insmed Inc
No recent average analyst rating found for Insmed Inc
Company Overview Insmed Inc
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey. Read Less
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease ...Read More
Frequently Asked Questions About Insmed Inc (INSM) Stock
Based on ratings from 14 analysts Insmed Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 33 buy, sell and hold ratings.
Unfortunately we do not have enough data on INSM's stock to indicate if its a good dividend stock.
Based on targets from 14 analysts, the average taret price for INSM is USD 75.91 over the next 12 months. The maximum analyst target price is USD 105 while the minimum anlayst target price is USD 40.
Unfortunately we do not have enough data on INSM's stock to indicate if its overvalued.
The last closing price of INSM's stock was USD 70.60.
The most recent market capitalization for INSM is USD 12.22B.
Based on targets from 14 analysts, the average taret price for INSM is projected at USD 75.91 over the next 12 months.
This means that INSM's stock price may go up by +7.52% over the next 12 months.
We can't find any ETFs which contains Insmed Inc's stock.
As per our most recent records Insmed Inc has 912 Employees.
Insmed Inc's registered address is 700 US Highway 202/206, Bridgewater, NJ, United States, 08807.
You can get more information about it from Insmed Inc's website at https://www.insmed.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Insmed Inc (INSM) Stock
Based on ratings from 14 analysts Insmed Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 33 buy, sell and hold ratings.
Unfortunately we do not have enough data on INSM's stock to indicate if its a good dividend stock.
Based on targets from 14 analysts, the average taret price for INSM is USD 75.91 over the next 12 months. The maximum analyst target price is USD 105 while the minimum anlayst target price is USD 40.
Unfortunately we do not have enough data on INSM's stock to indicate if its overvalued.
The last closing price of INSM's stock was USD 70.60.
The most recent market capitalization for INSM is USD 12.22B.
Based on targets from 14 analysts, the average taret price for INSM is projected at USD 75.91 over the next 12 months.
This means that INSM's stock price may go up by +7.52% over the next 12 months.
We can't find any ETFs which contains Insmed Inc's stock.
As per our most recent records Insmed Inc has 912 Employees.
Insmed Inc's registered address is 700 US Highway 202/206, Bridgewater, NJ, United States, 08807.
You can get more information about it from Insmed Inc's website at https://www.insmed.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for INSM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
